syngenta

2019 H1 Results

Basel, 22 July 2019

Cautionary statement regarding forward-looking statements

Some of the statements contained in this document are forward-looking statements. These statements are based on current expectations, assumptions, estimates and projections, and involve known and unknown risks, uncertainties and other factors that may cause results, levels of activity, performance or achievements to be materially different from any forward-looking statements. These statements are generally identified by words or phrases such as "believe", "anticipate", "expect", "intend", "plan", "will", "may", "should", "estimate", "predict", "potential", "continue" or the negative of such terms or other similar expressions. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results and the timing of events may differ materially from the results and/or timing discussed in the forward-looking statements, and you should not place undue reliance on these statements. Syngenta disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the period covered by this document or otherwise.



2019 H1 Financial Performance

- Sales \$6.8 billion: down 7%, 2% at CER*
 - Volumes impacted by severe flooding, delayed planting and reduced acres in the US
 - Emerging market price increase mitigated FX
- EBITDA \$1.5 billion: 15% lower, 9% at CER*
 - Margin 21.6% (2018: 23.6%): impacted by higher China raw material costs
- Net Income down 34% after 2018 divestment gains;
 6% lower excluding restructuring
- Free cash flow before acquisitions and US litigation settlement -\$0.3 billion (2018: \$0.7 billion); lower US sales and 2018 divestments






* Sales 6% lower, 1% at CER adjusted for divestments and change of control income under royalty agreements; EBITDA down 13%, 8% at CER on the same basis




H1 2019 sales* vs. prior year



* Growth adjusted for divestments and change of control royalty income




Half 1 2019 CP sales: -5%; 0% at CER*



* Variances versus PY adjusted for divestments; includes sales to Seeds



Half 1 2019 Seeds sales: -8%; -3% at CER*




Classification: PUBLIC

* Variances versus PY adjusted for divestments and change of control royalty income Regional sales excluding Vegetables and Flowers




6

H1 2019 EBITDA progression vs. prior year





H1 2019 net income vs. 2018



** Excludes restructuring and impairment related tax benefits



Net Income

\$m	2019	2018 Restated
Operating Income	1,135	1,412
Net financial expense	(219)	(185)
Taxation*	34	(219)
Tax rate	-4%	18%
Restructuring**	(152)	201
Net Income	798	1,209


All items except restructuring and net income exclude restructuring and impairment.

Net income as attributable to Syngenta shareholders; includes income from associates of \$2m (2018: \$1m) and net of non-controlling interests of \$2m (2018: \$1m)

- Includes one-off deferred tax revaluation gain of \$195m due to Swiss tax reform
- ** Net of tax



H1 2019 free cash flow vs. prior year



* 2018 includes \$408m receipt from antitrust divestments. 2019 includes \$267m proceeds from sale and leaseback of Basel site


** 2018 includes \$450m related to US settlements and \$80m for Monsanto change of control payment

H1 Results 2019 | 22 July 2019

10

Classification: PUBLIC Syngenta

Change in Net Debt:





11 H1 Results 2019 | 22 July 2019


Working Capital ratios

June 2017	June 2018		June 2019
48%	41%	Trade working capital as % of sales (month end)	44%
31%	32%	Inventories	37%
49%	42%	Trade Receivables	44%
32%	33%	Trade Payables	37%
47%	43%	Trade working capital as % of sales (average)	42%



2019 Update

- US market hit by major flooding, delayed planting and reduced acres
- Trade disputes
- Momentum maintained in Brazil
- Continued investment in innovation to drive sustainability agenda
- Expected market outperformance
- Low single digit sales growth
- Latam key to H2
- Solid free cash flow before Viptera settlement
 - \$1.1 bn paid H1 2019





Bringing plant potential to life

